trending Market Intelligence /marketintelligence/en/news-insights/trending/61xwlchhpupu2uzely0nlq2 content esgSubNav
In This List

Constellation Pharmaceuticals elects 2 directors to board

Video

S&P Capital IQ Pro | Powering Your Edge

Video

S&P Capital IQ Pro | Unrivaled Sector Coverage

Blog

Enterprises are missing out on 24B by not optimizing cloud spending not going multicloud

Blog

Investment Research Analysts Providing Greater Coverage on Inflation


Constellation Pharmaceuticals elects 2 directors to board

Constellation Pharmaceuticals Inc. said its board elected Elizabeth Trehu and Steven Hoerter as directors.

Trehu, who has 16 years of management experience at several biopharmaceutical companies, is currently the chief medical officer of Jounce Therapeutics Inc.

Hoerter is the chief commercial officer of Agios Pharmaceuticals Inc. where he built and leads the team responsible for the commercialization of the company's portfolio of medicines for cancer and rare genetic diseases.

The appointees "bring considerable experience working in the disease areas of myelofibrosis and prostate cancer that is directly relevant to Constellation’s clinical programs," Constellation Pharmaceuticals' President and CEO Jigar Raythatha said in a statement.

Constellation is advancing two lead clinical programs, one for CPI-1205 to treat a type of prostate cancer as well as solid tumors, and another for CPI-0610 — a potential treatment for myelofibrosis.